PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:07 AM ET

Sponsor Check › Person

JT
No photo found yet (own website and image search run after this page is viewed)

James Topper

Named as an officer, director or promoter on SEC Form D filings · WA, CA, MI, OH, IL · Apr 23, 2012 → Sep 11, 2025

24deals (issuers)
$4.01Breported sold
843investors
57Form D filings
2012–2025years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:22 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

James Topper is listed as an executive officer, director, and promoter on 57 SEC Form D filings by 24 issuers between Mar 2009 and Sep 2025. Largest by amount reported sold: Frazier Life Sciences XI, L.P. (Menlo Park, CA — pooled investment fund — 2022; $960M reported sold to 98 investors), Frazier Healthcare Growth Buyout Fund IX, L.P. (Seattle, WA — pooled investment fund — 2017–2018; $775.7M reported sold to 138 investors), Frazier Healthcare Growth Buyout Fund VIII, L.P. (Seattle, WA — pooled investment fund — 2015–2016; $519.6M reported sold to 67 investors), Frazier Life Sciences IX, L.P. (Seattle, WA — pooled investment fund — 2017; $418.9M reported sold to 55 investors), Frazier Healthcare VII, L.P. (Seattle, WA — pooled investment fund — 2012–2013; $293.9M reported sold to 37 investors) and 19 more (all listed below).

What this means That is a lot of deals — 24 separate companies raised money with this person listed as executive officer, director, and promoter, over about 16 years. Across those companies the filings report $4.01B sold in total.

Listed alongside Patrick Heron (16 shared filings), Alan Frazier (12 shared filings), Nader Naini (12 shared filings), Nathan Every (12 shared filings), Carol Gallagher (11 shared filings) and 118 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around James. Each name links to their own page.

The issuers belong to 3 sponsor groups: Frazier Healthcare (26 issuers, $2.74B reported sold, 2012–2026), Alpine Immune Sciences (2 issuers, $108M reported sold, 2014–2021) and Avalon (15 issuers, $705.3M reported sold, 2010–2025).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 5 bankruptcy cases matching the name listed in Key records below.

What this means 5 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared the newest 50 of 57 public filings for James Topper and found 21 differences, 3 worth asking the sponsor about: 4 bankruptcy cases name the subject or team members; James Topper appears on 3 deals that stopped filing before reaching their target; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for James Topper has not run yet — it is #31,810 of 47,349 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:22 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched James Topper..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

5 cases: 5 closed (disposition not in docket feed)

James D Topper closed
United States Bankruptcy Court, M.D. Florida · No. 6:03-bk-07174 · Filed Jun 20, 2003 · Closed Nov 14, 2003
Role of James D Topper: Debtor · Outcome: Case closed 2003-11-14 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 9 federal dockets); 5 people with this name in Form D filings; court in FL (not a filing state)
James E. Topper and Terri S. Topper closed
United States Bankruptcy Court, E.D. California · No. 03-92119 · Filed May 27, 2003 · Closed Aug 20, 2003
Role of James E. Topper and Terri S. Topper: Debtor · Outcome: Case closed 2003-08-20 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 9 federal dockets); 5 people with this name in Form D filings; court in the person's filing state (CA)
James E. Topper and Terri S. Topper closed
United States Bankruptcy Court, N.D. California · No. 02-46713 · Filed Dec 16, 2002 · Closed Apr 4, 2003
Role of James E. Topper and Terri S. Topper: Debtor · Outcome: Case closed 2003-04-04 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 9 federal dockets); 5 people with this name in Form D filings; court in the person's filing state (CA)
James Topper closed
United States Bankruptcy Court, N.D. New York · No. 02-66001 · Filed Oct 4, 2002 · Closed Mar 28, 2003
Role of James Topper: Debtor · Outcome: Case closed 2003-03-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 9 federal dockets); 5 people with this name in Form D filings; court in NY (not a filing state)
James L. Topper closed
United States Bankruptcy Court, W.D. Michigan · No. 00-03962 · Filed May 15, 2000 · Closed Apr 4, 2001
Role of James L. Topper: Debtor · Outcome: Case closed 2001-04-04 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 9 federal dockets); 5 people with this name in Form D filings; court in the person's filing state (MI)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:22 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

21 differences found between the filings for James Topper — 3 worth asking about (compared the newest 50 of 57 filings on Oct 24, 2026; older filings not covered)

Worth asking · Oct 4, 1999 – Aug 20, 2003

4 bankruptcy cases name the subject or team members

Bankruptcy case: James E. Topper and Terri S. Topper — filed May 27, 2003 · Bankruptcy case: James E. Topper and Terri S. Topper — filed Dec 16, 2002 · Bankruptcy case: James L. Topper — filed May 15, 2000 · Bankruptcy case: Juan De Dios Sandoval and Suria Sandoval Mansilla — filed Oct 4, 1999

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, E.D. California ↗Docket · United States Bankruptcy Court, N.D. California ↗Docket · United States Bankruptcy Court, W.D. Michigan ↗Docket · United States Bankruptcy Court, C.D. California ↗
Sources
Worth asking · Aug 16, 2013 – Dec 17, 2019

James Topper appears on 3 deals that stopped filing before reaching their target

Frazier Life Sciences X, L.P. (last filing Dec 17, 2019; $0 sold of $617,050,000); Alpine Immune Sciences, Inc. (last filing Jul 24, 2017; $17,000,004 sold of $47,999,998); Semnur Pharmaceuticals, Inc. (last filing Aug 16, 2013; $6,000,000 sold of $30,000,144). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Frazier Life Sciences X, L.P. — PartnerFacts page ↗Alpine Immune Sciences, Inc. — PartnerFacts page ↗Semnur Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Worth asking · Nov 15, 2011 – Aug 9, 2024

6 Form Ds were filed more than 15 days after the first sale

Form D filed 126 days after the first sale — Enlaza Therapeutics, Inc. · Form D filed 1,353 days after the first sale — Laguna Pharmaceuticals, Inc. · Form D filed 18 days after the first sale — Enlaza Therapeutics, Inc. · Form D filed 30 days after the first sale — Amunix Pharmaceuticals, Inc. · Form D filed 17 days after the first sale — Millendo Therapeutics, Inc. · and 1 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Aug 9, 2024 ↗Enlaza Therapeutics, Inc. — PartnerFacts page ↗Form D · Jul 30, 2015 ↗Laguna Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Oct 5, 2011 – Aug 9, 2024

26 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Enlaza Therapeutics, Inc. (latest filing Aug 9, 2024) · No amendment in the last 12 months on an offering that may still be open — Enlaza Therapeutics, Inc. (latest filing Nov 22, 2022) · No amendment in the last 12 months on an offering that may still be open — Enlaza Therapeutics, Inc. (latest filing Oct 13, 2022) · No amendment in the last 12 months on an offering that may still be open — Enlaza Therapeutics, Inc. (latest filing Oct 13, 2022) · No amendment in the last 12 months on an offering that may still be open — ALPINE IMMUNE SCIENCES, INC. (latest filing Sep 29, 2021) · and 21 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Aug 9, 2024 ↗Enlaza Therapeutics, Inc. — PartnerFacts page ↗Form D/A · Nov 22, 2022 ↗Form D · Oct 13, 2022 ↗
Sources
Note · Mar 25, 2021 – Nov 22, 2022

Offering amount changed between filings — Enlaza Therapeutics, Inc.

The Mar 25, 2021 filing says $21,273,287 offered; the Nov 22, 2022 Form D/A says $61,330,607.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Mar 25, 2021 ↗Form D/A (later) · Nov 22, 2022 ↗Enlaza Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jan 12, 2016 – Mar 23, 2016

Offering amount changed between filings — Frazier Healthcare Growth Buyout Fund VIII, L.P.

The Jan 12, 2016 filing says $500,000,000 offered; the Mar 23, 2016 Form D/A says $519,612,246.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D/A (earlier) · Jan 12, 2016 ↗Form D/A (later) · Mar 23, 2016 ↗Frazier Healthcare Growth Buyout Fund VIII, L.P. — PartnerFacts page ↗
Sources
Note · Oct 29, 2015 – Jan 12, 2016

Offering amount changed between filings — Frazier Healthcare Growth Buyout Fund VIII, L.P.

The Oct 29, 2015 filing says an indefinite amount offered; the Jan 12, 2016 Form D/A says $500,000,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Oct 29, 2015 ↗Form D/A (later) · Jan 12, 2016 ↗Frazier Healthcare Growth Buyout Fund VIII, L.P. — PartnerFacts page ↗
Sources
Note · Oct 29, 2015 – Jan 12, 2016

Minimum investment changed between filings — Frazier Healthcare Growth Buyout Fund VIII, L.P.

The Oct 29, 2015 filing lists a minimum of $0; the Jan 12, 2016 Form D/A lists $75,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Oct 29, 2015 ↗Form D/A (later) · Jan 12, 2016 ↗Frazier Healthcare Growth Buyout Fund VIII, L.P. — PartnerFacts page ↗
Sources
Note · Jul 3, 2012 – Sep 30, 2013

Minimum investment changed between filings — Frazier Healthcare VII, L.P.

The Jul 3, 2012 filing lists a minimum of $1,000,000; the Sep 30, 2013 Form D/A lists $50,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Jul 3, 2012 ↗Form D/A (later) · Sep 30, 2013 ↗Frazier Healthcare VII, L.P. — PartnerFacts page ↗
Sources
Note · Oct 14, 2011 – Dec 2, 2011

James Topper is written 2 different ways on the filings

listed as "James N. Topper" on 19 filings (from Oct 14, 2011), and "James Topper" on 31 filings (from Dec 2, 2011).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Oct 14, 2011 ↗Form D · Dec 2, 2011 ↗James Topper — PartnerFacts page ↗
Sources
Note · Oct 14, 2011 – Jul 24, 2015

Industry group changed between filings — ANAPTYSBIO INC

"Pharmaceuticals" (Oct 14, 2011 to Oct 10, 2013); then "Biotechnology" (Jul 24, 2015).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Oct 14, 2011 ↗Form D · Jul 24, 2015 ↗ANAPTYSBIO INC — PartnerFacts page ↗
Sources
Note · Apr 23, 2012 – Feb 26, 2013

Industry group changed between filings — Millendo Therapeutics, Inc.

"Pharmaceuticals" (Apr 23, 2012); then "Biotechnology" (Aug 3, 2012 to Sep 27, 2012); then "Pharmaceuticals" (Feb 26, 2013 to Dec 28, 2017).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Apr 23, 2012 ↗Form D · Aug 3, 2012 ↗Form D/A · Feb 26, 2013 ↗Millendo Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Dec 2, 2011 – Dec 21, 2011

Industry group changed between filings — PORTOLA PHARMACEUTICALS INC

"Pharmaceuticals" (Dec 2, 2011); then "Biotechnology" (Dec 21, 2011).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Dec 2, 2011 ↗Form D · Dec 21, 2011 ↗PORTOLA PHARMACEUTICALS INC — PartnerFacts page ↗
Sources
Note · Feb 23, 2021

Same name, different state: "James N. Topper" (MD) is a separate record

This page covers filings where the address state is WA or CA or MI or OH or IL. A separate record, "James N. Topper" with address state MD, is listed on 1 filing — most recently by Seraxis Holdings, Inc. (Feb 23, 2021). Both records have filings in the same period (Feb 23, 2021).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

James N. Topper (MD) — PartnerFacts page ↗Form D · Feb 23, 2021 ↗Seraxis Holdings, Inc. — PartnerFacts page ↗James Topper (WA,CA,MI,OH,IL) — this page ↗
Sources
Note · Nov 13, 2014 – Oct 31, 2016

Same name, different state: "James Topper" (MA or NJ) is a separate record

This page covers filings where the address state is WA or CA or MI or OH or IL. A separate record, "James Topper" with address state MA or NJ, is listed on 6 filings — most recently by Alcresta Therapeutics, Inc. (Sep 25, 2017). Both records have filings in the same period (Nov 13, 2014 to Oct 31, 2016).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

James Topper (MA,NJ) — PartnerFacts page ↗Form D · Sep 25, 2017 ↗Alcresta Therapeutics, Inc. — PartnerFacts page ↗James Topper (WA,CA,MI,OH,IL) — this page ↗
Sources
Note · Apr 29, 2016

Same name, different state: "James Topper" (PA) is a separate record

This page covers filings where the address state is WA or CA or MI or OH or IL. A separate record, "James Topper" with address state PA, is listed on 1 filing — most recently by Merganser Biotech, Inc. (Apr 29, 2016). Both records have filings in the same period (Apr 29, 2016).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

James Topper (PA) — PartnerFacts page ↗Form D/A · Apr 29, 2016 ↗Merganser Biotech, Inc. — PartnerFacts page ↗James Topper (WA,CA,MI,OH,IL) — this page ↗
Sources
Note · Nov 5, 2010 – Dec 3, 2013

Same name, different state: "James N. Topper" (NJ) is a separate record

This page covers filings where the address state is WA or CA or MI or OH or IL. A separate record, "James N. Topper" with address state NJ, is listed on 4 filings — most recently by AMICUS THERAPEUTICS, INC. (Dec 3, 2013). Both records have filings in the same period (Apr 23, 2012 to Dec 3, 2013).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

James N. Topper (NJ) — PartnerFacts page ↗Form D · Dec 3, 2013 ↗AMICUS THERAPEUTICS, INC. — PartnerFacts page ↗James Topper (WA,CA,MI,OH,IL) — this page ↗
Sources
Note · Jul 17, 2020 – Jan 21, 2021

Address moved from Mountain View, CA to South San Francisco, CA — Amunix Pharmaceuticals, Inc.

The people listed on the Jul 17, 2020 filing give Mountain View, CA; on the Jan 21, 2021 filing they give South San Francisco, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jul 17, 2020 ↗Form D · Jan 21, 2021 ↗Amunix Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Feb 26, 2013 – Jan 4, 2016

Address moved from Menlo Park, CA to Ann Arbor, MI — Millendo Therapeutics, Inc.

The people listed on the Feb 26, 2013 filing give Menlo Park, CA; on the Jan 4, 2016 filing they give Ann Arbor, MI.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D/A · Feb 26, 2013 ↗Form D · Jan 4, 2016 ↗Millendo Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Feb 17, 2015 – Jul 30, 2015

Address moved from Cleveland, OH to La Jolla, CA — Laguna Pharmaceuticals, Inc.

The people listed on the Feb 17, 2015 filing give Cleveland, OH; on the Jul 30, 2015 filing they give La Jolla, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Feb 17, 2015 ↗Form D · Jul 30, 2015 ↗Laguna Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Oct 14, 2011 – Sep 11, 2025

James Topper is listed with 5 different address states: CA, WA, MI, OH, IL

CA on 29 filings (Oct 14, 2011 to Sep 11, 2025); WA on 15 filings (Dec 2, 2011 to Sep 29, 2021); MI on 3 filings (May 1, 2014 to Dec 28, 2017); OH on 1 filing (Feb 17, 2015); IL on 2 filings (May 19, 2016 to Dec 21, 2017).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Oct 14, 2011 ↗Form D · Dec 2, 2011 ↗Form D · May 1, 2014 ↗Form D · Feb 17, 2015 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 57 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

3 of 47 offerings report sales commissions totalling $4,747,501; 1 reports finder's fees totalling $75,000; 1 reports proceeds to related persons totalling $15,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Sep 11, 2025 D
Enlaza Therapeutics, Inc.
File 021-557255
$0$0$0None listed on this filingEDGAR ↗
Mar 17, 2025 D
Frazier Life Sciences XII, L.P.
File 021-541158
$0$0$0None listed on this filingEDGAR ↗
Aug 9, 2024 D
Enlaza Therapeutics, Inc.
File 021-521146
$0$0$0None listed on this filingEDGAR ↗
Nov 22, 2022 D/A
Enlaza Therapeutics, Inc.
File 021-393460
$0$0$0None listed on this filingEDGAR ↗
Oct 13, 2022 D
Enlaza Therapeutics, Inc.
File 021-461688
$0$0$0None listed on this filingEDGAR ↗
Oct 13, 2022 D
Enlaza Therapeutics, Inc.
File 021-461697
$0$0$0None listed on this filingEDGAR ↗
Mar 18, 2022 D
Frazier Life Sciences XI, L.P.
File 021-438073
$0$0$0None listed on this filingEDGAR ↗
Sep 29, 2021 D
ALPINE IMMUNE SCIENCES, INC.
File 021-415077
$0$0$0None listed on this filingEDGAR ↗
Aug 13, 2021 D
Enlaza Therapeutics, Inc.
File 021-409959
$0$0$0None listed on this filingEDGAR ↗
Jun 28, 2021 D
Enlaza Therapeutics, Inc.
File 021-404438
$0$0$0None listed on this filingEDGAR ↗
Mar 9, 2021 D
Amunix Pharmaceuticals, Inc.
File 021-391600
$0$0$0None listed on this filingEDGAR ↗
Jan 21, 2021 D
Amunix Pharmaceuticals, Inc.
File 021-386939
$0$0$0None listed on this filingEDGAR ↗
Aug 7, 2020 D
ALPINE IMMUNE SCIENCES, INC.
File 021-372783
$3,340,002$0$0Cowen and Company BrokerCheck CRD 7616 ↗
Oppenheimer & Co. Inc. BrokerCheck CRD 249 ↗		EDGAR ↗
Jul 17, 2020 D
Amunix Pharmaceuticals, Inc.
File 021-371303
$0$0$0None listed on this filingEDGAR ↗
Mar 12, 2020 D
Amunix Pharmaceuticals, Inc.
File 021-362661
$0$0$0None listed on this filingEDGAR ↗
Dec 17, 2019 D
Frazier Life Sciences X, L.P.
File 021-355633
$0$0$0None listed on this filingEDGAR ↗
Jan 30, 2019 D
ALPINE IMMUNE SCIENCES, INC.
File 021-331755
$907,499$75,000$0Piper Jaffray & Co. BrokerCheck CRD 665 ↗EDGAR ↗
Apr 10, 2018 D/A
Frazier Healthcare Growth Buyout Affiliates IX, L.P.
File 021-300817
$0$0$0None listed on this filingEDGAR ↗
Apr 9, 2018 D/A
Frazier Healthcare Growth Buyout Fund IX, L.P.
File 021-300820
$0$0$0None listed on this filingEDGAR ↗
Dec 28, 2017 D
Millendo Therapeutics, Inc.
File 021-301902
$0$0$0None listed on this filingEDGAR ↗
Dec 21, 2017 D
Aptinyx Inc.
File 021-301461
$0$0$0None listed on this filingEDGAR ↗
Nov 1, 2017 D
Frazier Life Sciences IX, L.P.
File 021-297918
$0$0$0
The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement).
None listed on this filingEDGAR ↗
Jul 24, 2017 D
Alpine Immune Sciences, Inc.
File 021-291377
$0$0$0None listed on this filingEDGAR ↗
Jun 21, 2016 D
Alpine Immune Sciences, Inc.
File 021-265425
$0$0$0None listed on this filingEDGAR ↗
May 19, 2016 D
Aptinyx Inc.
File 021-263486
$0$0$0None listed on this filingEDGAR ↗
Mar 23, 2016 D/A
Frazier Healthcare Growth Buyout Fund VIII, L.P.
File 021-250280
$0$0$0
Frazier Management, L.L.C. receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the issuer's LPs.
None listed on this filingEDGAR ↗
Mar 23, 2016 D
Frazier Healthcare Growth Buyout Affiliates VIII, L.P.
File 021-259794
$0$0$0None listed on this filingEDGAR ↗
Jan 4, 2016 D
Millendo Therapeutics, Inc.
File 021-254446
$500,000$0$0Leerink Partners LLC BrokerCheck CRD 39011 ↗EDGAR ↗
Oct 29, 2015 D
Frazier Life Sciences VIII, L.P.
File 021-250272
$0$0$0
The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement).
None listed on this filingEDGAR ↗
Jul 30, 2015 D
Laguna Pharmaceuticals, Inc.
File 021-244746
$0$0$0None listed on this filingEDGAR ↗
Jul 24, 2015 D
ANAPTYSBIO INC
File 021-244446
$0$0$0None listed on this filingEDGAR ↗
Feb 17, 2015 D
Laguna Pharmaceuticals, Inc.
File 021-234194
$0$0$0None listed on this filingEDGAR ↗
May 1, 2014 D
ProNAi Therapeutics Inc
File 021-216611
$0$0$0 (est.)None listed on this filingEDGAR ↗
Oct 10, 2013 D
ANAPTYSBIO INC
File 021-204370
$0$0$0None listed on this filingEDGAR ↗
Sep 30, 2013 D/A
Frazier Healthcare VII, L.P.
File 021-180706
$0$0$0 (est.)
An affiliate of the General Partner will receive an investment advisory fee payable by the Issuer quarterly in advance. The investment advisory fee will generally be equal to a percentage of commitments as specified in the Issuer's constituent agreement.
None listed on this filingEDGAR ↗
Aug 16, 2013 D
Semnur Pharmaceuticals, Inc.
File 021-201465
$0$0$0None listed on this filingEDGAR ↗
May 8, 2013 D
Frazier Healthcare VII-A, L.P.
File 021-196141
$0$0$0 (est.)
The general partner or an affiliate thereof will receive a management fee payable by FH VII.
None listed on this filingEDGAR ↗
Feb 26, 2013 D/A
Millendo Therapeutics, Inc.
File 021-182187
$0$0$0None listed on this filingEDGAR ↗
Apr 23, 2012 D
Millendo Therapeutics, Inc.
File 021-177068
$0$0$15,000 (est.)None listed on this filingEDGAR ↗
Dec 21, 2011 D
PORTOLA PHARMACEUTICALS INC
File 021-170477
$0$0$0None listed on this filingEDGAR ↗
Dec 2, 2011 D
PORTOLA PHARMACEUTICALS INC
File 021-169528
$0$0$0None listed on this filingEDGAR ↗
Oct 14, 2011 D
ANAPTYSBIO INC
File 021-167334
$0$0$0None listed on this filingEDGAR ↗
Feb 7, 2011 D
ANAPTYSBIO INC
File 021-154949
$0$0$0None listed on this filingEDGAR ↗
Dec 27, 2010 D/A
CALISTOGA PHARMACEUTICALS INC
File 021-144409
$0$0$0None listed on this filingEDGAR ↗
Oct 21, 2010 D
ANAPTYSBIO INC
File 021-149377
$0$0$0None listed on this filingEDGAR ↗
Jan 20, 2010 D
Incline Therapeutics, Inc.
File 021-137971
$0$0$0None listed on this filingEDGAR ↗
May 14, 2009 D
CALISTOGA PHARMACEUTICALS INC
File 021-97987
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 24

Every issuer that named James Topper on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

ET
Pharmaceuticals · group: Avalon

Enlaza Therapeutics, Inc.

La Jolla, CA · Mar 25, 2021 → Sep 11, 2025 · 8 filings
  • Sep 11, 2025 · D · $15,000,000 sold of $15,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 9, 2024 · D · $84,000,000 sold of $110,000,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 22, 2022 · D/A · $35,299,237 sold of $61,330,607 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 13, 2022 · D · $0 sold of $311,977 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 13, 2022 · D · $0 sold of Indefinite · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 13, 2021 · D · $0 sold of Indefinite · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 28, 2021 · D · $0 sold of Indefinite · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 25, 2021 · D · $4,018,630 sold of $21,273,287 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $84M from 16 investors (100% of the $15M target) as of the latest filing. James is listed as director on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund

Frazier Life Sciences XII, L.P.

Palo Alto, CA · Mar 17, 2025
  • Mar 17, 2025 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer (Member of the General Partner of the General Partner) EDGAR ↗

No sales reported yet as of the latest filing. James is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund

Frazier Life Sciences XI, L.P.

Menlo Park, CA · Mar 18, 2022
  • Mar 18, 2022 · D · $960,000,000 sold of $960,000,000 · 98 investors · min. No minimum reported · role: Executive Officer (Member of the General Partner of the General Partner) EDGAR ↗

Raised $960M from 98 investors (100% of the $960M target) as of the latest filing. James is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AI
Biotechnology · group: Alpine Immune Sciences

ALPINE IMMUNE SCIENCES, INC.

Seattle, WA · Jan 30, 2019 → Sep 29, 2021 · 3 filings
  • Sep 29, 2021 · D · $90,999,934 sold of $91,003,125 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 7, 2020 · D · $60,000,013 sold of $82,666,486 · 25 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 30, 2019 · D · $25,274,979 sold of $48,660,651 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $91M from 25 investors (100% of the $91M target) as of the latest filing. James is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Biotechnology

Amunix Pharmaceuticals, Inc.

South San Francisco, CA · Mar 12, 2020 → Mar 9, 2021 · 4 filings
  • Mar 9, 2021 · D · $116,999,980 sold of $116,999,980 · 28 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 21, 2021 · D · $0 sold of $743,277 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 17, 2020 · D · $0 sold of $2,579,360 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 12, 2020 · D · $83,590,402 sold of $83,590,402 · 21 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $117M from 28 investors (100% of the $117M target) as of the latest filing. James is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund

Frazier Life Sciences X, L.P.

Seattle, WA · Dec 17, 2019
  • Dec 17, 2019 · D · $0 sold of $617,050,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of the General Partner of the General Partner) EDGAR ↗

No sales reported yet as of the latest filing. James is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Affiliates IX, L.P.

Seattle, WA · Dec 14, 2017 → Apr 10, 2018 · 2 filings
  • Apr 10, 2018 · D/A · $6,440,000 sold of Indefinite · 33 investors · min. No minimum reported · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Dec 14, 2017 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $6.44M from 33 investors as of the latest filing. James is listed as promoter on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Fund IX, L.P.

Seattle, WA · Dec 14, 2017 → Apr 9, 2018 · 2 filings
  • Apr 9, 2018 · D/A · $775,712,511 sold of Indefinite · 138 investors · min. No minimum reported · role: Promoter (Member of the Issuers' affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Dec 14, 2017 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Promoter (Member of the Issuers' affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $775.7M from 138 investors as of the latest filing. James is listed as promoter on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Pharmaceuticals

Millendo Therapeutics, Inc.

Ann Arbor, MI · Apr 23, 2012 → Dec 28, 2017 · 6 filings
  • Dec 28, 2017 · D · $50,043,201 sold of $59,109,960 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 4, 2016 · D · $47,697,172 sold of $70,702,987 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 26, 2013 · D/A · $8,522,872 sold of $16,633,013 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 27, 2012 · D/A · $3,506,411 sold of $16,633,013 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 3, 2012 · D · $1,506,411 sold of $16,633,013 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 23, 2012 · D · $250,000 sold of $500,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $50M from 21 investors (85% of the $59.1M target) as of the latest filing. James is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Pharmaceuticals

Aptinyx Inc.

Evanston, IL · May 19, 2016 → Dec 21, 2017 · 2 filings
  • Dec 21, 2017 · D · $70,000,000 sold of $70,000,000 · 63 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 19, 2016 · D · $24,999,999 sold of $65,000,000 · 48 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $70M from 63 investors (100% of the $70M target) as of the latest filing. James is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund · group: Frazier Healthcare

Frazier Life Sciences IX, L.P.

Seattle, WA · Nov 1, 2017
  • Nov 1, 2017 · D · $418,925,000 sold of $418,925,000 · 55 investors · min. No minimum reported · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $418.9M from 55 investors (100% of the $418.9M target) as of the latest filing. James is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AI
Biotechnology · group: Alpine Immune Sciences

Alpine Immune Sciences, Inc.

Seattle, WA · Jun 21, 2016 → Jul 24, 2017 · 2 filings
  • Jul 24, 2017 · D · $17,000,004 sold of $17,000,004 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 21, 2016 · D · $10,333,333 sold of $47,999,998 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $17M from 3 investors (100% of the $17M target) as of the latest filing. James is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Affiliates VIII, L.P.

Seattle, WA · Mar 23, 2016
  • Mar 23, 2016 · D · $5,000,000 sold of $5,000,000 · 21 investors · min. $100,000 · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $5M from 21 investors (100% of the $5M target) as of the latest filing. James is listed as promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Fund VIII, L.P.

Seattle, WA · Oct 29, 2015 → Mar 23, 2016 · 3 filings
  • Mar 23, 2016 · D/A · $519,612,246 sold of $519,612,246 · 67 investors · min. $75,000 · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Jan 12, 2016 · D/A · $435,000,000 sold of $500,000,000 · 62 investors · min. $75,000 · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Oct 29, 2015 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $519.6M from 67 investors (100% of the $519.6M target) as of the latest filing. James is listed as promoter on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund · group: Frazier Healthcare

Frazier Life Sciences VIII, L.P.

Seattle, WA · Oct 29, 2015
  • Oct 29, 2015 · D · $262,000,000 sold of $262,000,000 · 46 investors · min. $68,750 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $262M from 46 investors (100% of the $262M target) as of the latest filing. James is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LP
Pharmaceuticals

Laguna Pharmaceuticals, Inc.

La Jolla, CA · Feb 17, 2015 → Jul 30, 2015 · 2 filings
  • Jul 30, 2015 · D · $4,475,606 sold of $4,733,337 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 17, 2015 · D · $16,576,124 sold of $31,851,132 · 18 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $16.6M from 18 investors (100% of the $4.73M target) as of the latest filing. James is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Biotechnology

ANAPTYSBIO INC

San Diego, CA · Oct 21, 2010 → Jul 24, 2015 · 5 filings
  • Jul 24, 2015 · D · $40,767,277 sold of $40,767,277 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 10, 2013 · D · $2,022,117 sold of $6,250,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 14, 2011 · D · $8,024,394 sold of $21,975,606 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 7, 2011 · D · $14,400 sold of $14,400 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 21, 2010 · D · $9,600 sold of $9,600 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $40.8M from 19 investors (100% of the $40.8M target) as of the latest filing. James is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PT
Biotechnology

ProNAi Therapeutics Inc

Plymouth, MI · May 1, 2014
  • May 1, 2014 · D · $59,500,000 sold of $59,500,000 · 57 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $59.5M from 57 investors (100% of the $59.5M target) as of the latest filing. James is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare VII, L.P.

Seattle, WA · Jul 3, 2012 → Sep 30, 2013 · 2 filings
  • Sep 30, 2013 · D/A · $293,943,299 sold of $400,000,000 · 37 investors · min. $50,000 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗
  • Jul 3, 2012 · D · $0 sold of $400,000,000 · 0 investors · min. $1,000,000 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $293.9M from 37 investors (73% of the $400M target) as of the latest filing. James is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SP
Pharmaceuticals

Semnur Pharmaceuticals, Inc.

Mountain View, CA · Aug 16, 2013
  • Aug 16, 2013 · D · $6,000,000 sold of $30,000,144 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6M from 5 investors (20% of the $30M target) as of the latest filing. James is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare VII-A, L.P.

Seattle, WA · May 8, 2013
  • May 8, 2013 · D · $82,500,000 sold of $82,500,000 · 3 investors · min. $1,000,000 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $82.5M from 3 investors (100% of the $82.5M target) as of the latest filing. James is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

PP
Biotechnology

PORTOLA PHARMACEUTICALS INC

South San Francisco, CA · Dec 2, 2011 → Dec 21, 2011 · 2 filings
  • Dec 21, 2011 · D · $8,999,999 sold of $8,999,999 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 2, 2011 · D · $88,961,766 sold of $90,000,001 · 56 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $89M from 56 investors (100% of the $9M target) as of the latest filing. James is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

CP
Pharmaceuticals

CALISTOGA PHARMACEUTICALS INC

Seattle, WA · Mar 17, 2009 → Dec 27, 2010 · 4 filings
  • Dec 27, 2010 · D/A · $24,999,990 sold of $50,000,003 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 2, 2010 · D · $19,281,219 sold of $40,000,002 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 14, 2009 · D · $14,999,999 sold of $31,000,000 · 9 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Mar 17, 2009 · D · $1,000,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $25M from 17 investors (50% of the $50M target) as of the latest filing. James is listed as director, executive officer on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

IT
Biotechnology

Incline Therapeutics, Inc.

Redwood City, CA · Jan 20, 2010
  • Jan 20, 2010 · D · $440,000 sold of $440,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $22M from 17 investors (100% of the $440K target) as of the latest filing. James is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (4)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • James Topper — MA, NJ, 3 issuers, Nov 13, 2014 → Oct 31, 2016 · no shared issuer
  • James N. Topper — NJ, 1 issuer, Nov 5, 2010 → Dec 3, 2013 · no shared issuer
  • James Topper — PA, 1 issuer, Apr 29, 2016 → Apr 29, 2016 · no shared issuer
  • James N. Topper — MD, 1 issuer, Feb 23, 2021 → Feb 23, 2021 · no shared issuer

People around James 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

FM
Management entity

Frazier Management, L.L.C.

Promoter · 9 shared filings (5 issuers)

Frazier Management, L.L.C. is on 5 issuers in total — a repeat sponsor. Their page lists every one.

FG
Management entity

FHM Growth Buyout VIII, L.L.C.

Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as James Topper. Their page shows their other deals.

FG
Management entity

FHM Growth Buyout IX, L.L.C.

Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as James Topper. Their page shows their other deals.

FV
Management entity

FHM VII, L.L.C.

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as James Topper. Their page shows their other deals.

DF
Management entity

D. Frazier Management, L.L.C.

Promoter · 1 shared filing (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

FL
Management entity

FHM Life Sciences VIII, L.L.C.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

FI
Management entity

FHMLS IX, L.L.C.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

PH
No photo found yet (own website and image search run after this page is viewed)
Person

Patrick Heron

Executive Officer, Promoter · 16 shared filings (11 issuers) · also on 23 other issuers

Patrick Heron is on 34 issuers in total — a repeat sponsor. Their page lists every one.

NE
No photo found yet (own website and image search run after this page is viewed)
Person

Nathan Every

Executive Officer, Promoter · 12 shared filings (7 issuers) · also on 22 other issuers

Nathan Every is on 29 issuers in total — a repeat sponsor. Their page lists every one.

NN
No photo found yet (own website and image search run after this page is viewed)
Person

Nader Naini

Executive Officer, Promoter · 12 shared filings (7 issuers) · also on 22 other issuers

Nader Naini is on 29 issuers in total — a repeat sponsor. Their page lists every one.

AF
No photo found yet (own website and image search run after this page is viewed)
Person

Alan Frazier

Executive Officer, Promoter · 12 shared filings (7 issuers) · also on 5 other issuers

Alan Frazier is on 12 issuers in total — a repeat sponsor. Their page lists every one.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carol Gallagher

Executive Officer, Director · 11 shared filings (3 issuers) · also on 12 other issuers

Carol Gallagher is on 15 issuers in total — a repeat sponsor. Their page lists every one.

BM
No photo found yet (own website and image search run after this page is viewed)
Person

BRIAN MORFITT

Executive Officer · 8 shared filings (4 issuers) · also on 15 other issuers

BRIAN MORFITT is on 19 issuers in total — a repeat sponsor. Their page lists every one.

SC
No photo found yet (own website and image search run after this page is viewed)
Person

Shelley Chu

Director · 8 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as James Topper. Their page shows their other deals.

TR
No photo found yet (own website and image search run after this page is viewed)
Person

Tighe Reardon

Executive Officer · 8 shared filings (1 issuer) · also on 12 other issuers

Tighe Reardon is on 13 issuers in total — a repeat sponsor. Their page lists every one.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Jay Lichter

Director · 8 shared filings (1 issuer) · also on 9 other issuers

Jay Lichter is on 10 issuers in total — a repeat sponsor. Their page lists every one.

SM
No photo found yet (own website and image search run after this page is viewed)
Person

Sanford Madigan

Executive Officer · 8 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as James Topper. Their page shows their other deals.

SD
No photo found yet (own website and image search run after this page is viewed)
Person

Sergio Duron

Executive Officer, Director · 8 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as James Topper. Their page shows their other deals.

MM
No photo found yet (own website and image search run after this page is viewed)
Person

Marcos Milla

Director · 8 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

BM
No photo found yet (own website and image search run after this page is viewed)
Person

Ben Magnano

Executive Officer · 7 shared filings (4 issuers) · also on 16 other issuers

Ben Magnano is on 20 issuers in total — a repeat sponsor. Their page lists every one.

PT
No photo found yet (own website and image search run after this page is viewed)
Person

Peter A. Thompson

Director · 6 shared filings (3 issuers) · also on 26 other issuers

Peter A. Thompson is on 29 issuers in total — a repeat sponsor. Their page lists every one.

JO
No photo found yet (own website and image search run after this page is viewed)
Person

Julia C. Owens

Executive Officer, Director · 6 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

RW
No photo found yet (own website and image search run after this page is viewed)
Person

Randall Whitcomb

Director · 6 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

JV
No photo found yet (own website and image search run after this page is viewed)
Person

Jay Venkatesan

Executive Officer, Director · 5 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as James Topper. Their page shows their other deals.

MG
No photo found yet (own website and image search run after this page is viewed)
Person

Mitchell Gold

Executive Officer, Director · 5 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as James Topper. Their page shows their other deals.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Heyman

Director · 4 shared filings (1 issuer) · also on 7 other issuers

Richard Heyman is on 8 issuers in total — a repeat sponsor. Their page lists every one.

RL
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Lin

Director · 4 shared filings (1 issuer) · also on 12 other issuers

Richard Lin is on 13 issuers in total — a repeat sponsor. Their page lists every one.

RD
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Lee Douglas

Director · 4 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

WG
No photo found yet (own website and image search run after this page is viewed)
Person

W. Michael Gallatin

Executive Officer, Director, Promoter · 4 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

NL
No photo found yet (own website and image search run after this page is viewed)
Person

Nick Lydon

Director · 4 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

DH
No photo found yet (own website and image search run after this page is viewed)
Person

David Hirsch

Director · 4 shared filings (1 issuer) · also on 23 other issuers

David Hirsch is on 24 issuers in total — a repeat sponsor. Their page lists every one.

AY
No photo found yet (own website and image search run after this page is viewed)
Person

Angie You

Executive Officer, Director · 4 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as James Topper. Their page shows their other deals.

VS
No photo found yet (own website and image search run after this page is viewed)
Person

Volker Schellenberger

Executive Officer · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as James Topper. Their page shows their other deals.

JB
No photo found yet (own website and image search run after this page is viewed)
Person

James Brush

Director · 4 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

OS
No photo found yet (own website and image search run after this page is viewed)
Person

Otello Stampacchia

Director · 4 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

AC
No photo found yet (own website and image search run after this page is viewed)
Person

Aaron Coe

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

J Leighton Read

Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as James Topper. Their page shows their other deals.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

James Paul Rickey

Executive Officer · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as James Topper. Their page shows their other deals.

HL
No photo found yet (own website and image search run after this page is viewed)
Person

Heath Lukatch

Director · 3 shared filings (1 issuer) · also on 9 other issuers

Heath Lukatch is on 10 issuers in total — a repeat sponsor. Their page lists every one.

RC
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Conway

Director · 3 shared filings (1 issuer)

Listed on the same filings as James Topper. Their page shows their other deals.

The team behind the deals

FH
Sponsor group

Frazier Healthcare

26 issuers · 34 filings · $2.74B reported sold · 2012–2026

One team, 26 deal companies. James Topper is listed on 8 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name James Topper.

AI
Sponsor group

Alpine Immune Sciences

2 issuers · 8 filings · $108M reported sold · 2014–2021

One team, 2 deal companies. James Topper is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name James Topper.

A
Sponsor group

Avalon

15 issuers · 31 filings · $705.3M reported sold · 2010–2025

One team, 15 deal companies. James Topper is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name James Topper.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

A person is never an adviser firm. 5 of the 24 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): Frazier Healthcare Growth Buyout Affiliates IX, L.P., Frazier Healthcare Growth Buyout Fund IX, L.P., Frazier Life Sciences IX, L.P., Frazier Healthcare Growth Buyout Fund VIII, L.P., Frazier Healthcare Growth Buyout Affiliates VIII, L.P..

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to James Topper by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 24 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers James Topper is listed on: none on file. No website or social profile named in Frazier Life Sciences XI, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #161,427 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Menlo Park, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Washington Courts case search (dw.courts.wa.gov) ↗California — find the county court ↗Los Angeles Superior Court case search ↗Michigan state courts — find the court ↗Franklin County OH Clerk of Courts ↗Cook County Clerk of Court case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Washington Secretary of State business search ↗California Secretary of State business search ↗Michigan Secretary of State business search ↗Ohio Secretary of State business search ↗Illinois Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when James Topper appears on a new Form D, or when a court case or SEC action is matched to them. See plans →